Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$231.55
+0.5%
$239.43
$229.40
$287.32
$66.89B0.431.37 million shs738,143 shs
GSK plc stock logo
GSK
GSK
$41.12
+0.5%
$41.85
$33.33
$43.84
$85.22B0.643.44 million shs2.73 million shs
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
$306.60
-2.4%
$324.24
$215.96
$335.83
$81.09B1.651.11 million shs2.26 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$107.97
+1.7%
$102.15
$62.55
$142.79
$41.34B1.624.08 million shs2.25 million shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
-1.39%-1.15%-4.73%-2.58%-10.85%
GSK plc stock logo
GSK
GSK
+0.07%+4.16%-4.39%+4.71%+13.86%
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
-1.57%+5.76%-4.15%+10.83%+12.96%
Moderna, Inc. stock logo
MRNA
Moderna
-2.45%+4.10%-1.15%+4.29%-18.77%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
4.892 of 5 stars
2.45.03.34.02.82.52.5
GSK plc stock logo
GSK
GSK
2.3758 of 5 stars
0.03.03.30.01.80.02.5
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
4.7228 of 5 stars
2.43.01.74.53.72.52.5
Moderna, Inc. stock logo
MRNA
Moderna
4.0182 of 5 stars
3.12.00.04.61.83.30.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
2.80
Moderate Buy$280.0020.92% Upside
GSK plc stock logo
GSK
GSK
2.40
HoldN/AN/A
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
2.73
Moderate Buy$310.881.39% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.25
Hold$126.4917.15% Upside

Current Analyst Ratings

Latest HCA, GSK, BDX, and MRNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/12/2024
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$330.00 ➝ $359.00
4/11/2024
Moderna, Inc. stock logo
MRNA
Moderna
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold
4/10/2024
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$335.00
4/9/2024
Moderna, Inc. stock logo
MRNA
Moderna
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$125.00
4/1/2024
Moderna, Inc. stock logo
MRNA
Moderna
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
3/28/2024
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$303.00 ➝ $315.00
3/28/2024
Moderna, Inc. stock logo
MRNA
Moderna
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$125.00
3/28/2024
Moderna, Inc. stock logo
MRNA
Moderna
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold
3/6/2024
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$356.00
3/5/2024
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$335.00
3/4/2024
GSK plc stock logo
GSK
GSK
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$19.37B3.45$20.03 per share11.56$88.92 per share2.60
GSK plc stock logo
GSK
GSK
$37.71B2.26$5.22 per share7.88$7.74 per share5.31
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
$64.97B1.25$30.03 per share10.21$3.96 per share77.42
Moderna, Inc. stock logo
MRNA
Moderna
$6.85B6.04N/AN/A$36.33 per share2.97

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$1.48B$4.2254.8716.171.936.44%13.57%6.56%5/2/2024 (Confirmed)
GSK plc stock logo
GSK
GSK
$6.13B$3.0113.669.281.4416.24%51.45%10.57%5/1/2024 (Confirmed)
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
$5.24B$18.9816.1513.381.548.07%996.30%9.68%4/26/2024 (Confirmed)
Moderna, Inc. stock logo
MRNA
Moderna
-$4.71B-$12.41N/AN/AN/A-68.84%-10.23%-7.70%5/2/2024 (Confirmed)

Latest HCA, GSK, BDX, and MRNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/2/2024N/A
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$2.96N/A-$2.96N/AN/AN/A  
5/2/2024N/A
Moderna, Inc. stock logo
MRNA
Moderna
-$3.36N/A+$3.36N/AN/AN/A  
5/1/2024N/A
GSK plc stock logo
GSK
GSK
$0.95N/A-$0.95N/AN/AN/A
4/26/2024Q1 24
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
$5.01$5.36+$0.35N/A$16.81 billion$17.34 billion  
2/22/2024Q4 2023
Moderna, Inc. stock logo
MRNA
Moderna
-$0.78$0.55+$1.33$0.55$2.53 billion$2.80 billion    
2/1/2024Q1 2024
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$2.39$2.68+$0.29$4.40$4.73 billion$4.71 billion      
1/31/2024Q4 2023
GSK plc stock logo
GSK
GSK
$0.76$0.72-$0.04$1.23$9.79 billion$10.00 billion
1/30/202412/31/2023
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
$5.05$5.90+$0.85$5.87$16.51 billion$17.30 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$3.801.64%+4.77%90.05%52 Years
GSK plc stock logo
GSK
GSK
$1.593.87%-18.20%52.82%1 Years
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
$2.640.86%+50.79%13.91%4 Years
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A

Latest HCA, GSK, BDX, and MRNA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/26/2024
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
quarterly$0.660.84%6/14/20246/28/2024
2/1/2024
GSK plc stock logo
GSK
GSK
quarterly$0.35643.4%2/22/20242/23/20244/11/2024
1/30/2024
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
quarterly$0.660.92%3/14/20243/15/20243/29/2024
1/30/2024
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
quarterly$0.660.92%3/15/20243/29/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
0.56
1.08
0.64
GSK plc stock logo
GSK
GSK
1.19
0.88
0.62
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
35.07
1.18
1.02
Moderna, Inc. stock logo
MRNA
Moderna
0.04
3.42
3.36

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
86.97%
GSK plc stock logo
GSK
GSK
15.74%
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
62.73%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%

Insider Ownership

CompanyInsider Ownership
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
0.31%
GSK plc stock logo
GSK
GSK
10.00%
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
1.60%
Moderna, Inc. stock logo
MRNA
Moderna
15.70%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
73,000288.90 million288.01 millionOptionable
GSK plc stock logo
GSK
GSK
70,2002.07 billion1.87 billionOptionable
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
310,000264.48 million260.25 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
5,600382.88 million322.77 millionOptionable

HCA, GSK, BDX, and MRNA Headlines

SourceHeadline
Moderna (MRNA) Surpasses Market Returns: Some Facts Worth KnowingModerna (MRNA) Surpasses Market Returns: Some Facts Worth Knowing
zacks.com - April 26 at 7:06 PM
World-First mRNA Vaccine For Skin Cancer Commences Landmark Phase 3 TrialWorld-First mRNA Vaccine For Skin Cancer Commences Landmark Phase 3 Trial
iflscience.com - April 26 at 1:49 PM
Moderna banks on OpenAI to accelerate mRNA researchModerna banks on OpenAI to accelerate mRNA research
pharmaphorum.com - April 26 at 8:49 AM
California Public Employees Retirement System Lowers Stake in Moderna, Inc. (NASDAQ:MRNA)California Public Employees Retirement System Lowers Stake in Moderna, Inc. (NASDAQ:MRNA)
marketbeat.com - April 26 at 7:36 AM
Should You Buy Moderna Before May 12?Should You Buy Moderna Before May 12?
fool.com - April 26 at 4:50 AM
Moderna cancer vaccine offers long-term hope in melanomaModerna cancer vaccine offers long-term hope in melanoma
proactiveinvestors.co.uk - April 26 at 4:06 AM
How Is The Market Feeling About Moderna?How Is The Market Feeling About Moderna?
benzinga.com - April 26 at 3:49 AM
British patients test world’s first personalised MRNA cancer jab for melanomaBritish patients test world’s first personalised MRNA cancer jab for melanoma
yahoo.com - April 26 at 3:49 AM
Cancer cure hope as UK patients trial world’s first personalised mRNA vaccine for melanomaCancer cure hope as UK patients trial world’s first personalised mRNA vaccine for melanoma
msn.com - April 26 at 3:49 AM
British patients test world’s first personalised mRNA jab for melanomaBritish patients test world’s first personalised mRNA jab for melanoma
expressandstar.com - April 25 at 10:49 PM
Stevens Capital Management LP Cuts Stake in Moderna, Inc. (NASDAQ:MRNA)Stevens Capital Management LP Cuts Stake in Moderna, Inc. (NASDAQ:MRNA)
marketbeat.com - April 25 at 6:01 PM
Modernas CEO wants employees to use ChatGPT at least 20 times a dayModerna's CEO wants employees to use ChatGPT at least 20 times a day
msn.com - April 25 at 5:47 PM
Moderna lifts lid on OpenAI artificial intelligence collabModerna lifts lid on OpenAI artificial intelligence collab
thepharmaletter.com - April 25 at 5:47 PM
Moderna Employees Should Use ChatGPT at Least 20 Times a Day, CEO SaysModerna Employees Should Use ChatGPT at Least 20 Times a Day, CEO Says
msn.com - April 25 at 5:47 PM
Analysts Estimate Moderna (MRNA) to Report a Decline in Earnings: What to Look Out forAnalysts Estimate Moderna (MRNA) to Report a Decline in Earnings: What to Look Out for
zacks.com - April 25 at 11:05 AM
Moderna, Inc.: Moderna To Present Respiratory & Cytomegalovirus Research at the ESCMID Global CongressModerna, Inc.: Moderna To Present Respiratory & Cytomegalovirus Research at the ESCMID Global Congress
finanznachrichten.de - April 25 at 8:26 AM
Moderna To Present Respiratory & Cytomegalovirus Research at the ESCMID Global CongressModerna To Present Respiratory & Cytomegalovirus Research at the ESCMID Global Congress
accesswire.com - April 25 at 7:00 AM
Moderna (MRNA) to Release Earnings on ThursdayModerna (MRNA) to Release Earnings on Thursday
americanbankingnews.com - April 25 at 3:42 AM
Sycomore Asset Management Invests $4.67 Million in Moderna, Inc. (NASDAQ:MRNA)Sycomore Asset Management Invests $4.67 Million in Moderna, Inc. (NASDAQ:MRNA)
marketbeat.com - April 24 at 10:27 PM
How mRNA Is Rewriting the Rules of Cancer TreatmentHow mRNA Is Rewriting the Rules of Cancer Treatment
scitechdaily.com - April 24 at 10:24 PM
Moderna partners with OpenAI to supercharge mRNA research with genAIModerna partners with OpenAI to supercharge mRNA research with genAI
mmm-online.com - April 24 at 5:24 PM
Moderna Stock Jumps On Collaboration With OpenAI: Whats Going On?Moderna Stock Jumps On Collaboration With OpenAI: What's Going On?
msn.com - April 24 at 12:24 PM
Moderna and OpenAI in pact to fast-track drug developmentModerna and OpenAI in pact to fast-track drug development
msn.com - April 24 at 12:24 PM
Moderna and OpenAI Collaborate To Advance mRNA MedicineModerna and OpenAI Collaborate To Advance mRNA Medicine
accesswire.com - April 24 at 8:00 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Becton, Dickinson and Company logo

Becton, Dickinson and Company

NYSE:BDX
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
GSK logo

GSK

NYSE:GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
HCA Healthcare logo

HCA Healthcare

NYSE:HCA
HCA Healthcare, Inc., through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy. The company also operates outpatient health care facilities consisting of freestanding ambulatory surgery centers, freestanding emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, rehabilitation and physical therapy centers, radiation and oncology therapy centers, physician practices, and various other facilities. In addition, it operates behavioral hospitals, which provide therapeutic programs comprising child, adolescent and adult psychiatric care, adolescent and adult alcohol, drug abuse treatment, and counseling services. The company was formerly known as HCA Holdings, Inc. HCA Healthcare, Inc. was founded in 1968 and is headquartered in Nashville, Tennessee.
Moderna logo

Moderna

NASDAQ:MRNA
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.